Bio Medica Laboratories Limited (BMLL)

Bio Medica Laboratories Limited has announced the voting results of its 11th Annual General Meeting held on September 28, 2026. All four resolutions were passed with 100% of polled votes in favour, representing 83.47% overall voting participation across 10,496,541 polled shares. Notably, shareholders passed a special resolution approving an increase in the investment limit for registered Foreign Portfolio Investors (FPIs) / Foreign Institutional Investors (FIIs) up to 49% of the paid-up equity share capital. Other approved resolutions included the adoption of FY26 financial statements, the reappointment of director Mr. Mukesh Mehta, and the appointment of the secretarial auditor.

• Special resolution passed to increase total FPI/FII shareholding limit up to 49% of paid-up equity capital
• Overall voter turnout stood at 83.4715% with 10,496,541 votes polled out of 12,575,001 total shares
• All resolutions passed unanimously with 100% of votes cast in favour and 0 votes against
• Only 18 shareholders attended the AGM via video conference (2 promoters and 16 public shareholders)

Bio Medica Laboratories Limited concluded its 11th Annual General Meeting on September 28, 2026. Shareholders approved all four proposed resolutions, including the adoption of FY26 financial statements and the reappointment of director Mukesh Mehta. Notably, a special resolution was passed approving an increase in the investment limit for Registered FPIs and FIIs up to 49% of the paid-up equity share capital. Secretarial auditor appointment and remuneration were also approved.

• Shareholders approved increasing the FPI/FII shareholding limit up to 49% of paid-up equity capital via a special resolution
• Adoption of audited financial statements for the financial year ended March 31, 2026
• Re-appointment of Whole-time Director Mukesh Mehta (DIN: 03187420) approved
• 11th AGM held on September 28, 2026, commencing at 02:09 P.M. and concluding at 02:25 P.M.

Bio Medica Laboratories Limited has issued the notice convening its 11th Annual General Meeting (AGM) on September 28, 2026, via video conferencing. The company is seeking shareholder approval for routine business, including the adoption of FY26 financial statements and director re-appointment. Notably, a special resolution is proposed to increase the collective investment limit for Foreign Portfolio Investors (FPIs)/FIIs up to 49% of the paid-up equity share capital. Additionally, the appointment of M/s Vishakha Agrawal & Associates as Secretarial Auditor for a 5-year tenure is placed for approval.

• 11th AGM scheduled for September 28, 2026, at 02:00 PM IST via video conferencing
• Special resolution proposed to raise FPI/FII shareholding limit up to 49% of paid-up equity share capital
• Appointment of Secretarial Auditor M/s Vishakha Agrawal & Associates for a term of 5 years (FY26 to FY31)
• Adoption of audited financial statements for the financial year ended March 31, 2026

Bio Medica Laboratories Limited has announced remote e-voting facilities for its 11th Annual General Meeting scheduled for Monday, September 28, 2026. The cut-off date to determine shareholder voting eligibility is Tuesday, September 22, 2026. Remote e-voting opens on Friday, September 25, 2026, and concludes on Sunday, September 27, 2026, at 5:00 PM IST via the NSDL platform. CS Vishakha Agrawal has been appointed as the scrutinizer for the process.

• 11th Annual General Meeting scheduled for Monday, September 28, 2026
• Cut-off date for e-voting eligibility set for Tuesday, September 22, 2026
• Remote e-voting window runs from September 25, 2026, to September 27, 2026 (5:00 PM)
• NSDL to act as the e-voting platform provider with CS Vishakha Agrawal appointed as Scrutinizer

Bio Medica Laboratories Limited has announced that its 11th Annual General Meeting (AGM) will be held on Monday, September 28, 2026, at 2:00 PM IST via video conferencing. The company's Register of Members and Share Transfer Books will remain closed from September 23, 2026, to September 28, 2026 (both days inclusive) for the purpose of the AGM. The exchange brief indicates a record date of September 22, 2026. This is a standard annual compliance and corporate governance announcement.

• 11th Annual General Meeting scheduled for September 28, 2026, at 02:00 P.M.
• Share transfer books and register of members closed from September 23, 2026, to September 28, 2026
• Record date for meeting eligibility set as September 22, 2026
• AGM to be conducted electronically via Video Conferencing / Other Audio Visual Means

Bio Medica Laboratories Limited has approved the appointment of M/s. Vishakha Agrawal & Associates, Practicing Company Secretaries, as its Secretarial Auditor. The appointment took place at the Board meeting held on September 02, 2026. The tenure covers a period of 5 consecutive years spanning FY 2025-26 to FY 2029-30. The appointment is subject to approval by shareholders at the ensuing Annual General Meeting.

• Board approved appointment on September 02, 2026
• Appointed M/s. Vishakha Agrawal & Associates as Secretarial Auditor
• Tenure spans 5 consecutive years from FY 2025-26 to FY 2029-30
• Appointment remains subject to shareholder approval at the upcoming AGM

Bio Medica Laboratories Limited has approved the convening of its 11th Annual General Meeting (AGM) on September 28, 2026, via Video Conferencing. The cut-off date for electronic voting eligibility is set as September 22, 2026, with the remote e-voting window active from September 25 to September 27, 2026. Additionally, the Board approved the appointment of M/s. Vishakha Agrawal & Associates as the Secretarial Auditor for a five-year term spanning FY 2025-26 to FY 2029-30, subject to shareholder approval.

• 11th AGM scheduled for September 28, 2026, at 02:00 PM via Video Conferencing
• Shareholder voting cut-off date fixed for September 22, 2026
• Book closure period set from September 23, 2026, to September 28, 2026
• Remote e-voting window runs from September 25, 2026 (09:00 AM) to September 27, 2026 (05:00 PM)
• M/s. Vishakha Agrawal & Associates appointed as Secretarial Auditor for 5 consecutive years (FY 2025-26 to FY 2029-30)

Bio Medica Laboratories Limited (BMLL) announced the approval of all four postal ballot resolutions by shareholders with 100% of votes cast in favor. The key approval includes a Special Resolution to sell and disinvest the company's 51% equity shareholding in its subsidiary, Vitamax Private Limited. Additionally, shareholders approved higher thresholds for loans, guarantees, and securities under Sections 185 and 186, as well as material related-party transactions under Section 188. Out of 12,575,001 total outstanding equity shares, 10,336,541 shares (82.20% turnout) participated in the remote e-voting.

• 100% of votes cast (10,336,541 votes) were in favour of selling the 51% stake in subsidiary Vitamax Private Limited
• Overall voting turnout was 82.20% across 18 participating shareholders out of 347 total members
• Promoter group polled 8,512,541 votes (99.9957% of promoter holding), all in favour
• Shareholders also approved enhanced limits for inter-corporate loans, guarantees, and investments under Sections 185 and 186

Bio Medica Laboratories Limited (BMLL) has appointed Ms. Khushi Gupta as Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP) effective August 14, 2026. This appointment fills a casual vacancy created by the resignation of the previous officer. Ms. Gupta is a qualified Company Secretary and an Associate Member of the Institute of Company Secretaries of India (ICSI). The board approved the appointment following a recommendation from the Nomination & Remuneration Committee.

• Appointment of Ms. Khushi Gupta effective from August 14, 2026
• Ms. Gupta is an Associate Member of ICSI with Membership No. A78179
• The role covers Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP) designations
• Appointment fills a casual vacancy arising from the resignation of the previous incumbent

Bio Medica Laboratories Limited (BMLL) has announced a change in its Key Managerial Personnel (KMP) following a board meeting on August 14, 2026. Ms. Pratiksha Bhandari resigned from the position of Company Secretary and Compliance Officer effective August 13, 2026, citing personal reasons. The board has concurrently appointed Ms. Khushi Gupta, an Associate Member of ICSI, to the role effective August 14, 2026. This transition appears to be a routine administrative replacement to ensure continuous regulatory compliance.

• Resignation of Ms. Pratiksha Bhandari effective from the close of business hours on August 13, 2026
• Appointment of Ms. Khushi Gupta as Company Secretary and Compliance Officer effective August 14, 2026
• Board meeting conducted for a duration of 30 minutes, from 11:00 A.M. to 11:30 A.M.
• New appointee Ms. Khushi Gupta holds ICSI membership number A78179

Bio Medica Laboratories Limited has announced the resignation of Ms. Pratiksha Bhandari from the post of Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP). Her resignation is effective from the close of business hours on August 13, 2026. The resignation is cited to be purely due to personal reasons and other professional commitments, with no other material reasons reported. The company will be required to appoint a successor to maintain statutory compliance.

• Ms. Pratiksha Bhandari resigned as Company Secretary, Compliance Officer, and KMP.
• Resignation effective from the close of business hours on August 13, 2026.
• Stated reason: Personal reasons and other professional commitments with no other material reasons.

Bio Medica Laboratories Limited has announced the resignation of Ms. Pratiksha Bhandari from her role as Whole-Time Company Secretary, Compliance Officer, and Key Managerial Personnel. The resignation is effective from the close of business hours on August 13, 2026. The stated reasons for departure are personal reasons and other professional commitments, with no other material reasons reported. The company will need to appoint a successor to fulfill statutory compliance requirements.

• Ms. Pratiksha Bhandari tendered resignation as CS, Compliance Officer, and KMP effective close of business hours on August 13, 2026
• Departure attributed to personal reasons and other professional commitments
• Filing confirms no other material reasons for the resignation

Bio Medica Laboratories Limited has announced the resignation of Ms. Pratiksha Bhandari from the post of Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP). The resignation took effect from the close of business hours on August 13, 2026. The stated reason for her departure is personal reasons and other professional commitments, with no other material reasons cited.

• Resignation of Ms. Pratiksha Bhandari as Company Secretary, Compliance Officer, and KMP
• Effective cessation date: Close of business hours of August 13, 2026
• Reason cited: Personal reasons and other professional commitments

Bio Medica Laboratories Limited (BMLL) has announced the resignation of Ms. Pratiksha Bhandari from the positions of Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP). The resignation is effective from the close of business hours on August 13, 2026. The departure is attributed to personal reasons and other professional commitments, with no other material reasons cited. The company is now required to appoint a successor to maintain regulatory compliance and secretarial standards.

• Resignation effective from the close of business hours on August 13, 2026
• Ms. Pratiksha Bhandari held the role of Company Secretary and Compliance Officer (Membership No. A36256)
• Departure cited as being due to personal reasons and other professional commitments
• The Board of Directors noted the resignation during their meeting on August 13, 2026

Bio Medica Laboratories Limited (BMLL) has informed the exchange that it is exempt from submitting the Corporate Governance Report for the quarter ended June 30, 2026. This exemption is granted under Regulation 15(2) of SEBI (LODR) Regulations, 2015, which applies to entities listed on the SME Exchange. The regulation specifically exempts companies with a paid-up equity capital not exceeding ₹10 crore and a net worth not exceeding ₹25 crore. As an NSE SME Platform listed entity, BMLL is not required to comply with the governance provisions specified in Regulations 17 to 27.

• Exemption claimed under Regulation 15(2) of SEBI (LODR) Regulations, 2015 for the quarter ended June 30, 2026.
• Exemption applies to SME entities with paid-up capital not exceeding ₹10 crore.
• Exemption applies to SME entities with net worth not exceeding ₹25 crore.
• The company is listed on the NSE SME Platform, qualifying it for reduced reporting requirements.